Furiex Pharmaceuticals Stock Price, News & Analysis (NASDAQ:FURX)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Furiex Pharmaceuticals (NASDAQ:FURX)

Furiex Pharmaceuticals logoFuriex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Receive FURX News and Ratings via Email

Sign-up to receive the latest news and ratings for FURX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Life Sciences Tools & Services
Sub-IndustryLife Sciences Tools & Services


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Furiex Pharmaceuticals (NASDAQ:FURX) Frequently Asked Questions

What is Furiex Pharmaceuticals' stock symbol?

Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."

Who are some of Furiex Pharmaceuticals' key competitors?

Has Furiex Pharmaceuticals been receiving favorable news coverage?

Media coverage about FURX stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Furiex Pharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also gave news stories about the healthcare company an impact score of 45.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Furiex Pharmaceuticals?

Shares of FURX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Furiex Pharmaceuticals?

Furiex Pharmaceuticals' mailing address is 3900 Paramount Pkwy Ste 150, MORRISVILLE, NC 27560-5401, United States. The healthcare company can be reached via phone at +1-919-4567800.

MarketBeat Community Rating for Furiex Pharmaceuticals (FURX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  128
MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Furiex Pharmaceuticals (NASDAQ:FURX) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Furiex Pharmaceuticals (NASDAQ:FURX) Earnings History and Estimates Chart

Earnings by Quarter for Furiex Pharmaceuticals (NASDAQ:FURX)

Furiex Pharmaceuticals (NASDAQ FURX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2014Q114($0.63)($1.25)$10.01 million$6.40 millionViewN/AView Earnings Details
3/11/2014Q413($1.06)($0.63)$12.80 million$13.10 millionViewN/AView Earnings Details
11/5/2013Q3 2013($1.33)($0.85)$21.30 million$15.55 millionViewN/AView Earnings Details
8/6/2013Q2 2013($1.65)($2.32)$11.94 million$3.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.70$0.82$33.42 million$39.33 millionViewN/AView Earnings Details
3/6/2013Q4 2012($2.04)($0.90)$7.43 million$9.21 billionViewN/AView Earnings Details
11/1/2012Q3 2012($0.90)($0.33)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.47)($2.09)ViewN/AView Earnings Details
5/3/2012Q1 2012($1.37)($0.98)ViewN/AView Earnings Details
2/21/2012Q4 2011($0.68)ViewN/AView Earnings Details
11/1/2011Q3 2011($1.53)($1.32)ViewN/AView Earnings Details
8/3/2011Q2 2011($1.51)ViewN/AView Earnings Details
4/28/2011Q1 2011($1.45)ViewN/AView Earnings Details
2/21/2011Q4 2010($1.18)ViewN/AView Earnings Details
11/10/2010Q3 2010($2.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Furiex Pharmaceuticals (NASDAQ:FURX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Furiex Pharmaceuticals (NASDAQ:FURX)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Furiex Pharmaceuticals (NASDAQ FURX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Furiex Pharmaceuticals (NASDAQ:FURX)

Furiex Pharmaceuticals (NASDAQ FURX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/24/2014Paul S CovingtonVPSell10,368$104.12$1,079,516.16View SEC Filing  
6/24/2014Sailash PatelCFOSell32,928$104.00$3,424,512.00View SEC Filing  
6/18/2014Paul S CovingtonVPSell45,691$104.11$4,756,890.01View SEC Filing  
6/17/2014Gail Frances McintyreSVPSell74,457$105.01$7,818,729.57View SEC Filing  
6/13/2014Paul S CovingtonVPSell3,228$104.25$336,519.00View SEC Filing  
6/10/2014Gail Frances McintyreSVPSell1,746$104.58$182,596.68View SEC Filing  
6/10/2014Paul S CovingtonVPSell2,872$104.63$300,497.36View SEC Filing  
6/10/2014Sailash PatelCFOSell1,504$104.68$157,438.72View SEC Filing  
9/10/2013Paul S CovingtonVPSell30,000$40.89$1,226,700.00View SEC Filing  
8/9/2013Peter CorrDirectorSell7,500$39.74$298,050.003,580View SEC Filing  
7/19/2013Gail Frances McintyreSVPSell10,581$40.00$423,240.00View SEC Filing  
3/12/2013Stephen W KaldorDirectorSell6,352$41.58$264,116.16View SEC Filing  
8/15/2012June Sherie AlmenoffPresidentBuy1,000$18.67$18,670.00View SEC Filing  
(Data available from 1/1/2013 forward)


Furiex Pharmaceuticals (NASDAQ FURX) News Headlines

No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Furiex Pharmaceuticals (NASDAQ:FURX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Furiex Pharmaceuticals (NASDAQ:FURX) Income Statement, Balance Sheet and Cash Flow Statement


Furiex Pharmaceuticals (NASDAQ FURX) Stock Chart for Monday, March, 19, 2018

Loading chart…

This page was last updated on 3/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.